80O Patient (pt) preference and satisfaction with the subcutaneous fixed-dose combination of pertuzumab (P) and trastuzumab (H) in pts with HER2-positive early breast cancer (HER2+ eBC): Interim analysis of the open-label, randomised cross-over PHranceSCa study

A subcutaneous fixed-dose combination of P + H (PH FDC SC) may offer pts less invasive, faster administration vs intravenous P + H (PH IV). PHranceSCa is an open-label, randomised cross-over study evaluating pt preference and satisfaction with PH FDC SC vs PH IV. Pts with histologically confirmed, HER2+ eBC who completed neoadjuvant therapy with P + H + chemotherapy and had surgery are enrolled and 1:1 randomised to Group A: 3 cycles of PH IV...